Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance

Journal of the American College of Cardiology

Volumn 68, Issue 16, 2016, Pages 1769-1780

  Choudhury, Robin P ^a   Birks, Jacqueline S ^a   Mani, Venkatesh ^b   Biasiolli, Luca ^a   Robson, Matthew D ^a   L'Allier, Philippe L ^c,d   Gingras, Marc Alexandre ^c,d   Alie, Nadia ^e   McLaughlin, Mary Ann ^b   Basson, Craig T ^e   Schecter, Alison D ^e   Svensson, Eric C ^e   Zhang, Yiming ^e   Yates, Denise ^e   Tardif, Jean Claude ^c,d   Fayad, Zahi A ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MONTREAL HEART INSTITUTE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

C reactive protein; homeostasis model assessment; inflammation; interleukin 1

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; INTERLEUKIN 6; LIPOPROTEIN A; PLACEBO; TRIACYLGLYCEROL; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ADULT; AORTA; ARTERY COMPLIANCE; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE INTOLERANCE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; ARTERY; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; ARTERIES; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED;

EID: 84994506061     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.07.768     Document Type: Article

References (36)

1. 1 Libby, P., Inflammation in atherosclerosis. Nature 420 (2002), 868–874.
2. 2 Libby, P., Ridker, P.M., Maseri, A., Inflammation and atherosclerosis. Circulation 105 (2002), 1135–1143.
3. 3 Ross, R., Atherosclerosis—an inflammatory disease. N Engl J Med 340 (1999), 115–126.
4. 4 Ridker, P.M., Hennekens, C.H., Buring, J.E., Rifai, N., C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000), 836–843.
5. 5 Ridker, P.M., Rifai, N., Pfeffer, M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98 (1998), 839–844.
6. 6 Ridker, P.M., Cushman, M., Stampfer, M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997), 973–979.
7. 7 Ridker, P.M., Rifai, N., Pfeffer, M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100 (1999), 230–235.
8. 8 Tipping, P.G., Hancock, W.W., Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am J Pathol 142 (1993), 1721–1728.
9. 9 Duewell, P., Kono, H., Rayner, K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (2010), 1357–1361.
10. 10 Kirii, H., Niwa, T., Yamada, Y., et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol 23 (2003), 656–660.
11. 11 Elhage, R., Maret, A., Pieraggi, M.T., et al. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 97 (1998), 242–244.
12. 12 Isoda, K., Sawada, S., Ishigami, N., et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 24 (2004), 1068–1073.
13. 13 Merhi-Soussi, F., Kwak, B.R., Magne, D., et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 66 (2005), 583–593.
14. 14 Ikonomidis, I., Lekakis, J.P., Nikolaou, M., et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117 (2008), 2662–2669.
15. 15 Maedler, K., Sergeev, P., Ris, F., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110 (2002), 851–860.
16. 16 Larsen, C.M., Faulenbach, M., Vaag, A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356 (2007), 1517–1526.
17. 17 Stratton, I.M., Adler, A.I., Neil, H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000), 405–412.
18. 18 Moreno, P.R., Murcia, A.M., Palacios, I.F., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102 (2000), 2180–2184.
19. 19 Lee, J.M., Shirodaria, C., Jackson, C.E., et al. Multi-modal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 4 (2007), 44–48.
20. 20 Ridker, P.M., Howard, C.P., Walter, V., et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126 (2012), 2739–2748.
21. 21 Ridker, P.M., Thuren, T., Zalewski, A., Libby, P., Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162 (2011), 597–605.
22. 22 Duivenvoorden, R., de Groot, E., Elsen, B.M., et al. In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging. Circ Cardiovasc Imaging 2 (2009), 235–242.
23. 23 Fayad, Z.A., Mani, V., Woodward, M., et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378 (2011), 1547–1559.
24. 24 Lee, J.M., Robson, M.D., Yu, L.M., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 54 (2009), 1787–1794.
25. 25 Wiesmann, F., Petersen, S.E., Leeson, P.M., et al. Global impairment of brachial, carotid, and aortic vascular function in young smokers: direct quantification by high-resolution magnetic resonance imaging. J Am Coll Cardiol 44 (2004), 2056–2064.
26. 26 Cruickshank, K., Riste, L., Anderson, S.G., et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 106 (2002), 2085–2090.
27. 27 Biasiolli, L., Lindsay, A.C., Chai, J.T., et al. In-vivo quantitative T2 mapping of carotid arteries in atherosclerotic patients: segmentation and T2 measurement of plaque components. J Cardiovasc Magn Reson, 15, 2013, 69.
28. 28 Elkhawad, M., Rudd, J.H., Sarov-Blat, L., et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. J Am Coll Cardiol Img 5 (2012), 911–922.
29. 29 Tawakol, A., Migrino, R.Q., Bashian, G.G., et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48 (2006), 1818–1824.
30. 30 El Kasmi, K.C., Stenmark, K.R., Contribution of metabolic reprogramming to macrophage plasticity and function. Semin Immunol 27 (2015), 267–275.
31. 31 Sica, A., Mantovani, A., Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122 (2012), 787–795.
32. 32 Dutta, P., Courties, G., Wei, Y., et al. Myocardial infarction accelerates atherosclerosis. Nature 487 (2012), 325–329.
33. 33 Sager, H.B., Heidt, T., Hulsmans, M., et al. Targeting interleukin-1beta reduces leukocyte production after acute myocardial infarction. Circulation 132 (2015), 1880–1890.
34. 34 Alexander, M.R., Moehle, C.W., Johnson, J.L., et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest 122 (2012), 70–79.
35. 35 Saiki, O., Takao, R., Naruse, Y., et al. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J Rheumatol 34 (2007), 1997–2004.
36. 36 Lindsay, A.C., Choudhury, R.P., Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov 7 (2008), 517–529.